Influência do biofeedback respiratório associado ao padão quiet breathing sobre a função pulmonar e hábitos de respiradores bucais funcionais / Influence of respiratory biofeedback associated with a quiet breathing pattern on the pulmonary function and habits of functional mouth breathers

OBJETIVOS: Avaliar os efeitos da utilização do biofeedback respiratório (BR) associado ao padrão quiet breathing sobre a perimetria torácica, função pulmonar, força dos músculos respiratórios e os seguintes hábitos de respiradores bucais funcionais (RBF): vigília de boca aberta, boca aberta durante o sono, baba no travesseiro, despertar difícil, ronco e sono inquieto. MÉTODOS: Foram avaliadas 20 crianças RBF, as quais foram submetidas a 15 sessões de BR por meio do biofeedback pletsmovent (MICROHARD® V1.0), o qual proporciona o biofeedback dos movimentos tóraco-abdominais. Perimetria torácica, espirometria e medidas das pressões respiratórias máximas estáticas foram realizadas antes e após a terapia. Questões respondidas pelos responsáveis foram utilizadas para avaliar os hábitos dos RBF. Os dados foram analisados por meio de teste t de Student para dados pareados e testes não paramétricos. RESULTADOS: O uso do BR associado ao padrão quiet breathing não produziu alterações significativas na perimetria torácica e nos valores de volume expiratório forçado no primeiro segundo (VEF1), capacidade vital forçada (CVF), pico de fluxo expiratório (PFE), índice de Tiffeneau (IT) e na pressão expiratória máxima (PEmáx). Entretanto, a pressão inspiratória máxima (PImáx) apresentou diferença estatisticamente significativa (-53,6 ± 2,9 cmH2O vs. -65,0 ± 6,0 cmH2O; p< 0,05) e ocorreram mudanças significativas nos hábitos avaliados. CONCLUSÃO: Os resultados permitem concluir que o BR associado ao padrão quiet breathing melhora a força da musculatura inspiratória e hábitos em RBF, podendo ser, portanto, utilizado como uma das formas de terapia nesses indivíduos.

OBJECTIVE: To evaluate the effects of using respiratory biofeedback associated with a quiet breathing pattern, on chest circumference, pulmonary function, respiratory muscle strength and the following functional mouth-breathing habits: watching things with mouth open, sleeping with mouth open, dribbling on the pillow, difficulty in waking up, snoring and restlessness during sleep. METHOD: Twenty functional mouth-breathing children were evaluated. They underwent 15 sessions of respiratory biofeedback by means of the biofeedback pletsmovent (MICROHARD® V1.0), which provided biofeedback on thoracoabdominal movements. Chest circumference, spirometry and maximum static respiratory pressures were determined before and after the therapy. The adults responsible for these children were asked questions about the children's mouth-breathing habits. Student's t test for paired data and non-parametric tests were used to analyze the data. RESULTS: The use of respiratory biofeedback in association with a quiet breathing pattern did not produce significant alterations in chest circumference or in forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), Tiffeneau index (TI) or maximal expiratory pressure (MEP). However, there was a significant difference in maximal inspiratory pressure (MIP) (-53.6 ± 2.9 cmH2O vs. -65.0 ± 6.0 cmH2O; p< 0.05) and there were significant changes in the evaluated habits. CONCLUSION: The results allow the conclusion that respiratory biofeedback associated with a quiet breathing pattern improves the inspiratory muscle strength and habits of functional mouth-breathers. It can therefore be used as a therapeutic method for such individuals.

Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.

The purpose of this study was to evaluate gemcitabine plus paclitaxel in heavily pretreated patients with metastatic breast cancer (MBC). Patients with MBC with second or third relapse to anthracycline-containing regimens received a 3-hour infusion of paclitaxel 175 mg/m2 on day 1, and gemcitabine 1.0 g/m2 on days 1, 8, and 15, every 28 days. Because of unacceptable thrombocytopenia seen in the first 5 patients, the gemcitabine schedule was changed to days 1 and 8 (G-1,8) for the remainder of the study, every 21 days. Twenty-nine patients (median age, 46 years; range, 32-68 years) received 137 cycles (median: 4 per patient). The regimen was well tolerated. World Health Organization grades III and IV thrombocytopenia were observed in 5 (18.5%) of the first 27 cycles (G-1,8,15), and in 6 (5.4%) of the 110 subsequent cycles (G-1,8)--p = 0.04 for the difference between schedules. Five patients had grade I and two had grade III neuropathy. Eight patients had grade III neutropenia, two had grade IV neutropenia associated with fever (G-1,8,15), and eight had grades I and II myalgia and fatigue. There were 16 (55%) objective responses (95% CI 36-73%); 5 (17%) complete responses, 11 (38%) partial responses (95% CI 3-30% and 19-56%, respectively), and 6 (20.5%) patients with stable disease. Median response duration was 8 months (range, 4-26 months). Median overall survival was 12 months (range, 4-28+ months), and 1-year and 2-year survival rates were 45% and 30%, respectively. This phase II study demonstrated a manageable toxicity profile with the gemcitabine day 1, 8 schedule in combination with paclitaxel and significant and promising activity in heavily pretreated patients with MBC. A confirmatory phase III trial is warranted.

Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.

In a phase II trial, 29 patients with anthracycline-pretreated or anthracycline-resistant metastatic breast cancer in whom anthracycline-containing first- or second-line chemotherapy failed received combination paclitaxel (Taxol)/gemcitabine (Gemzar). The initial regimen of paclitaxel at 175 mg/m2 on day 1 and gemcitabine at 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle was given to five patients for a total of 27 cycles. The regimen resulted in excessive thrombocytopenia and was subsequently changed to gemcitabine at the same dose on days 1 and 8 of a 21-day cycle, with study treatment being given for a maximum of eight cycles. This regimen was well tolerated. Further evaluation of this regimen in minimally and heavily pretreated patients with advanced breast cancer is warranted.

Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.

This prospective phase II clinical trial was performed to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric adenocarcinoma. Thirty-one patients ages 18 to 70 years, with Karnofsky performance status (KPS) >50, adequate cardiac, renal, and hepatic functions, measurable metastatic or locally unresectable disease, life expectancy > or =3 months, signed written informed consent, and without any previous chemotherapy were assigned to receive on an outpatient basis: paclitaxel--175 mg/m2, in a 3-hour infusion on day 1 and 5-fluorouracil--1.5 g/m2, also in a 3-hour infusion on day 2 every 21 days, for a maximum of seven cycles. A system to assess clinical benefit based on KPS, analgesic consumption, and weight gain was also used in this trial. Median age was 61 years (range, 31-70 years). The 29 patients eligible for response and toxicity evaluation underwent 147 cycles of chemotherapy. There were 19 (65.5%) objective responses (95% confidence interval: 48%-83%), including 7 (24.1%) complete responses and 12 (41.4%) partial responses. Three patients had the complete response pathologically confirmed. In three of six patients who went to second-look laparotomy, a potentially curative esophagogastrectomy was possible. The toxicity of this combination was considered low, predictable, and manageable and was characterized mainly by reversible alopecia, peripheral neuropathy, myalgia, and mild neutropenia. Fifteen (51.7%) patients attained a clinical benefit response. The median overall survival was 12 months (range, 2-30+ months) and the 30-month overall survival was 20%. This novel regimen appears to be very effective in advanced gastric cancer. The projected 2-year survival of 20% is higher than that achieved with other first-line regimens. These encouraging results indicate the need for further studies to confirm the merit of this regimen.

Correlação entre a atividade plasmática da creatinoquinase MB e o eletrocardiograma convencional no infarto agudo do miocárdio / Correlation of plasma activity of creatine kinase MB and conventional electrocardiogram in acute myocardial infarction

Em 17 pacientes portadores de infarto agudo do miocardio foram obtidos quatro eletrocardiogramas convencionais no momento da internacao (ECGo) e no primeiro (ECG1), terceiro (ECG3) e quinto (ECG5) dias de evolucao. Foi estudada a possibilidade de correlacao entre variaveis eletricas de isquemia (segmento ST) e de necrose (ondas R, Q e grau de Q) e a massa infartada (MI) calculada atraves de analise da atividade plasmatica da fracao MB da creatinoquinase, por periodo de ate 48 horas. O retardo medio entre o inicio dos sintomas e o ECGo foi de 3,16 horas.A analise dos resultados mostrou nao haver correlacao significativa entre a somatoria dos segmento ST, a da onda R, a da onda Q e do grau Q com o valor de MI, fato que se mostrou inclusive independente da localizacao topografica e do tamanho do infarto. Os resultados sugerem que o eletrocardiograma convencional apresenta importantes limitacoes na quantificacao do processo isquemico no infarto agudo do miocardio